.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Queensland Health
Chubb
Fuji
Cipla
Harvard Business School
Cerilliant
Medtronic
UBS
Chinese Patent Office

Generated: November 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,200,604

« Back to Dashboard

Which drugs does patent 6,200,604 protect, and when does it expire?


Patent 6,200,604 protects FENTORA and is included in one NDA. There has been one Paragraph IV challenge on Fentora.

This patent has thirty-two patent family members in twelve countries.

Summary for Patent: 6,200,604

Title: Sublingual buccal effervescent
Abstract:A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.
Inventor(s): Pather; Sathasivan Indiran (Plymouth, MN), Khankari; Rajendra K. (Maple Grove, MN), Eichman; Jonathan D. (Ann Arbor, MI), Robinson; Joseph R. (Madison, WI), Hontz; John (Plymouth, MN)
Assignee: Cima Labs Inc. (Minneapolis, MN)
Application Number:09/327,814
Patent Claim Types:
see list of patent claims
Use; Dosage form; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Cephalon
FENTORA
fentanyl citrate
TABLET;BUCCAL, SUBLINGUAL021947-001Sep 25, 2006RXYesNo► Subscribe► Subscribe MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
Cephalon
FENTORA
fentanyl citrate
TABLET;BUCCAL, SUBLINGUAL021947-002Sep 25, 2006RXYesNo► Subscribe► Subscribe MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
Cephalon
FENTORA
fentanyl citrate
TABLET;BUCCAL, SUBLINGUAL021947-006Mar 2, 2007DISCNYesNo► Subscribe► Subscribe MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
Cephalon
FENTORA
fentanyl citrate
TABLET;BUCCAL, SUBLINGUAL021947-003Sep 25, 2006RXYesYes► Subscribe► Subscribe MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
Cephalon
FENTORA
fentanyl citrate
TABLET;BUCCAL, SUBLINGUAL021947-004Sep 25, 2006RXYesNo► Subscribe► Subscribe MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
Cephalon
FENTORA
fentanyl citrate
TABLET;BUCCAL, SUBLINGUAL021947-005Sep 25, 2006RXYesNo► Subscribe► Subscribe MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,200,604

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,974,590 Sublingual buccal effervescent► Subscribe
6,350,470 Effervescent drug delivery system for oral administration► Subscribe
6,576,250 Pharmaceutical compositions for rectal and vaginal administration► Subscribe
8,765,100Transmucosal effervescent► Subscribe
6,764,696 Effervescent drug delivery system for oral administration► Subscribe
6,509,036 Effervescent drug delivery system for oral administration► Subscribe
8,728,441Sublingual buccal effervescent► Subscribe
6,391,335 Effervescent drug delivery system for oral administration► Subscribe
6,641,838 Effervescent drug delivery system for oral administration► Subscribe
8,802,130Sublingual buccal effervescent► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,200,604

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1419765► Subscribe
Portugal1417959► Subscribe
Portugal1082106► Subscribe
Japan2002543109► Subscribe
Japan4954170► Subscribe
Japan2009029829► Subscribe
Japan4789324► Subscribe
Japan2002540141► Subscribe
Hong Kong1130691► Subscribe
Spain2383478► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
US Department of Justice
AstraZeneca
Healthtrust
Chubb
McKesson
McKinsey
Medtronic
Dow
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot